Delgocitinib, a Janus kinase (JAK) inhibitor, is the subject of U.S. Patent US11673900B2, which outlines a manufacturing process for the drug [1]. The patent was granted to Opta Pharma Research Co., Ltd. [1].
What is Delgocitinib used for?
Delgocitinib is a topical medication approved for treating atopic dermatitis, also known as eczema [2]. It targets multiple types of JAKs, which are involved in the inflammatory pathways that contribute to this skin condition [2].
What does the patent US11673900B2 specifically cover?
U.S. Patent US11673900B2 details an improved method for producing delgocitinib. The process described aims to enhance purity and yield while potentially reducing impurities, making the manufacturing more efficient and cost-effective [1].
When does the patent for Delgocitinib expire?
Information regarding the specific expiry date of U.S. Patent US11673900B2, or other patents covering delgocitinib, is not available in the provided information. Drug patent expiry can be complex, involving multiple patents covering the drug substance, its formulation, and manufacturing processes. DrugPatentWatch.com is a resource that tracks such patent information [3].
Who developed Delgocitinib?
The development of delgocitinib is associated with Opta Pharma Research Co., Ltd., the assignee of U.S. Patent US11673900B2 [1].
What are the potential side effects of Delgocitinib?
While specific side effects were not detailed in the patent information, as a JAK inhibitor, common side effects can include infections, acne, and headache. Patients should consult with their healthcare provider for a comprehensive list of potential side effects [2].
How does Delgocitinib work?
Delgocitinib works by inhibiting Janus kinases (JAKs). These enzymes play a crucial role in signaling pathways that drive inflammation in conditions like atopic dermatitis. By blocking JAKs, delgocitinib reduces the inflammatory response in the skin [2].
What are the alternatives to Delgocitinib for atopic dermatitis?
Treatments for atopic dermatitis vary and may include topical corticosteroids, other topical immunomodulators, and systemic therapies for more severe cases. The choice of treatment depends on the severity of the condition and individual patient factors [2].
---
Citations:
[1] https://patents.google.com/patent/US11673900B2/en
[2] https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-delgocitinib-topical-treatment-moderate-severe-atopic-dermatitis
[3] https://drugpatentwatch.com/